Peter Eimon joined Tevard Biosciences in 2018 as a Principal Scientist with over 15 years of experience in drug development and neuroscience research. Most recently Peter served as a Research Scientist at the Massachusetts Institute of Technology in the High-Throughput Neurotechnology Group, a multidisciplinary team addressing fundamental questions related to the function and treatment of the central nervous system. While there, Peter managed projects in diverse areas including using genome editing to develop animal models of neurological disorders, optimizing virus-free protocols for generation of induced pluripotent stem cells, and devising in vivo assays for neuroactive drugs based on ultra-fast imaging of whole-brain neuronal activity patterns.
In 2016 he was a recipient of MIT’s Infinite Mile Award, which is given to select individuals and teams in recognition of outstanding achievement. Prior to joining MIT, Peter served as a Senior Scientist for a biotechnology company that applies high-throughput small animal models to drug discovery and safety pharmacology, with particular interest in Alzheimer’s and Parkinson’s disease.
Peter completed his Ph.D. in molecular and cell biology at the University of California, Berkeley and worked as a postdoctoral researcher at Genentech. He has served as a scientific consultant for biotechnology startups focused on anti-epileptic drug discovery, given invited talks at various international conferences, and co-authored numerous peer-reviewed publications, review articles, and invited book chapters.